Acute Diarrhea in a Tertiary Emergency Department: From Readmission Determinants to Antibiotic Prescription
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients and Setting
2.2. Data Collection
- -
- Characteristics of ED access, including self-reported or transferred by the emergency medical system (EMS); triage code assigned, length of stay in the ED (hours);
- -
- Patient demographics, including age and sex;
- -
- Onset of diarrhea (before or after 24 h since ED admission);
- -
- Refusal of hospitalization;
- -
- Associated complains at ED admission, including fever over >37.5 °C, vomiting, nausea, abdominal pain, chest pain, syncope, melena, rectorrhagia, belching/hiccups, malaise;
- -
- Clinical history, including the presence of diverticulosis, gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), cardiac disease, chronic obstructive pulmonary disease (COPD), diabetes, chronic renal failure, liver disease;
- -
- Laboratory evaluation (if obtained), including white blood count (WBC), C-reactive protein (CRP) value, hemoglobin (Hb) values, serum creatinine, and serum procalcitonin (if obtained). Laboratory tests were available 24 h/day in our institution in the study period;
- -
- Prescription of any antibiotic at discharge. Antibiotic prescriptions were grouped for into non-absorbable and absorbable antibiotics further analysis. The search list of absorbable antibiotics includes amoxicillin, amoxicillin/clavulanic acid (Am/Cl), ceftriaxone, azithromycin, clarithromycin, ciprofloxacin, levofloxacin, fluoroquinolones, metronidazole, vancomycin, and doxycycline;
- -
- Prescription of probiotics at discharge, alone or in combination with antibiotics.
2.3. Outcome Measures
2.4. Statistical Analyses
3. Results
3.1. Study Population
3.2. Determinants of ED Readmission within Seven Days in the Total Cohort
3.3. Determinants of ED Readmission within Seven Days According to Age Subgroups
3.4. Antibiotic Prescription
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Riddle, M.S.; DuPont, H.L.; Connor, B.A. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. Am. J. Gastroenterol. 2016, 111, 602–622. [Google Scholar] [CrossRef] [PubMed]
- GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024, 403, 2133–2161. [Google Scholar] [CrossRef]
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1204–1222. [Google Scholar] [CrossRef]
- Farthing, M.; Salam, M.A.; Lindberg, G.; Dite, P.; Khalif, I.; Salazar-Lindo, E.; Ramakrishna, B.S.; Goh, K.L.; Thomson, A.; Khan, A.G.; et al. Acute diarrhea in adults and children: A global perspective. J. Clin. Gastroenterol. 2013, 47, 12–20. [Google Scholar] [CrossRef] [PubMed]
- Ghosh, S.; Malik, Y.S.; Kobayashi, N. Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future. Curr. Drug Metab. 2018, 19, 170–191. [Google Scholar] [CrossRef]
- Huhulescu, S.; Kiss, R.; Brettlecker, M.; Cerny, R.J.; Hess, C.; Wewalka, G.; Allerberger, F. Etiology of acute gastroenteritis in three sentinel general practices, Austria 2007. Infection 2009, 37, 103–108. [Google Scholar] [CrossRef] [PubMed]
- Bresee, J.S.; Marcus, R.; Venezia, R.A.; Keene, W.E.; Morse, D.; Thanassi, M.; Brunett, P.; Bulens, S.; Beard, R.S.; Dauphin, L.A.; et al. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. J. Infect. Dis. 2012, 205, 1374–1381. [Google Scholar] [CrossRef] [PubMed]
- Shane, A.L.; Mody, R.K.; Crump, J.A.; Tarr, P.I.; Steiner, T.S.; Kotloff, K.; Langley, J.M.; Wanke, C.; Warren, C.A.; Cheng, A.C.; et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2017, 65, e45–e80. [Google Scholar] [CrossRef]
- Jabak, S.J.; Kawam, L.; El Mokahal, A.; Sharara, A.I. Management of acute diarrhea in the emergency department of a tertiary care university medical center. J. Int. Med. Res. 2022, 50, 3000605221115385. [Google Scholar] [CrossRef]
- Karras, D.J.; Ong, S.; Moran, G.J.; Nakase, J.; Kuehnert, M.J.; Jarvis, W.R.; Talan, D.A.; EMERGEncy ID NET Study Group. Antibiotic use for emergency department patients with acute diarrhea: Prescribing practices, patient expectations, and patient satisfaction. Ann. Emerg. Med. 2003, 42, 835–842. [Google Scholar] [CrossRef]
- Biswas, D.; Hossin, R.; Rahman, M.; Bardosh, K.L.; Watt, M.H.; Zion, M.I.; Sujon, H.; Rashid, M.M.; Salimuzzaman, M.; Flora, M.S.; et al. An ethnographic exploration of diarrheal disease management in public hospitals in Bangladesh: From problems to solutions. Soc. Sci. Med. 2020, 260, 113185. [Google Scholar] [CrossRef] [PubMed]
- Benson, A.B., 3rd; Ajani, J.A.; Catalano, R.B.; Engelking, C.; Kornblau, S.M.; Martenson, J.A., Jr.; McCallum, R.; Mitchell, E.P.; O’Dorisio, T.M.; Vokes, E.E.; et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2004, 22, 2918–2926. [Google Scholar] [CrossRef]
- Terrin, M.; Migliorisi, G.; Dal Buono, A.; Gabbiadini, R.; Mastrorocco, E.; Quadarella, A.; Repici, A.; Santoro, A.; Armuzzi, A. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. Int. J. Mol. Sci. 2023, 24, 11504. [Google Scholar] [CrossRef]
- Cortel-LeBlanc, M.A.; Lemay, K.; Woods, S.; Bakewell, F.; Liu, R.; Garber, G. Medico-legal risk and use of medical directives in the emergency department. CJEM 2023, 25, 589–597. [Google Scholar] [CrossRef]
- Kenny, J.F.; Chang, B.C.; Hemmert, K.C. Factors Affecting Emergency Department Crowding. Emerg. Med. Clin. N. Am. 2020, 38, 573–587. [Google Scholar] [CrossRef] [PubMed]
- Tan, R.; Huang, Z.; Guo, H.; Weng, Y.; Chow, A. Antibiotic expectations of patients attending an emergency department with upper respiratory tract infections: Clinical and behavioural determinants of antibiotic use. Int. J. Antimicrob. Agents 2022, 59, 106511. [Google Scholar] [CrossRef]
- White, M.B.; Rajagopalan, S.; Yoshikawa, T.T. Infectious Diarrhea: Norovirus and Clostridium difficile in Older Adults. Clin. Geriatr. Med. 2016, 32, 509–522. [Google Scholar] [CrossRef] [PubMed]
- Guh, A.Y.; Mu, Y.; Winston, L.G.; Johnston, H.; Olson, D.; Farley, M.M.; Wilson, L.E.; Holzbauer, S.M.; Phipps, E.C.; Dumyati, G.K.; et al. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N. Engl. J. Med. 2020, 382, 1320–1330. [Google Scholar] [CrossRef]
- Mada, P.K.; Alam, M.U. Clostridioides difficile infection. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
- Ward, D.D.; Ranson, J.M.; Wallace, L.M.K.; Llewellyn, D.J.; Rockwood, K. Frailty, lifestyle, genetics and dementia risk. J. Neurol. Neurosurg. Psychiatry 2022, 93, 343–350. [Google Scholar] [CrossRef]
- Assar, M.E.; Laosa, O.; Rodríguez Mañas, L. Diabetes and frailty. Curr. Opin Clin. Nutr. Metab. Care 2019, 22, 52–57. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Wang, Y.; Shen, L.; Sun, Y.; Zeng, B.; Zhu, B.; Dai, F. Association between frailty and chronic constipation and chronic diarrhea among American older adults: National Health and Nutrition Examination Survey. BMC Geriatr. 2023, 23, 745. [Google Scholar] [CrossRef] [PubMed]
- Hanlon, P.; Nicholl, B.I.; Jani, B.D.; Lee, D.; McQueenie, R.; Mair, F.S. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: A prospective analysis of 493 737 UK Biobank participants. Lancet Public Health 2018, 3, e323–e332. [Google Scholar] [CrossRef] [PubMed]
- Huemer, M.; Mairpady Shambat, S.; Brugger, S.D.; Zinkernagel, A.S. Antibiotic resistance and persistence-Implications for human health and treatment perspectives. EMBO Rep. 2020, 21, e51034. [Google Scholar] [CrossRef] [PubMed]
- Paul, M.; Pulia, M.; Pulcini, C. Antibiotic stewardship in the emergency department: Not to be overlooked. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2021, 27, 172–174. [Google Scholar] [CrossRef]
- Carestia, M.; Andreoni, M.; Buonomo, E.; Ciccacci, F.; De Angelis, L.; De Carolis, G.; De Filippis, P.; Di Giovanni, D.; Emberti Gialloreti, L.; Fontana, C.; et al. A novel, integrated approach for understanding and investigating Healthcare Associated Infections: A risk factors constellation analysis. PLoS ONE 2023, 18, e0282019. [Google Scholar] [CrossRef]
Variable | All Patients N 20,581 | 18–65 Years-Old N 15,063 | >65 Years-Old N 5518 | p Value |
---|---|---|---|---|
Sex (male) | 8107 (39.4) | 6035 (40.1) | 2072 (37.5) | 0.001 |
Age (years) | 48 (33–66) | 40 (29–51) | 76 (70–82) | 0.000 |
Length of stay in the ED (hours) | 7.2 [4.6–14.5] | 6.7 [4.4–11.8] | 9.0 [5.4–23.9] | 0.000 |
Triage code | ||||
Emergency | 120 (0.6) | 62 (0.4) | 58 (1.1) | 0.000 |
Urgent | 5548 (27) | 3543 (23.5) | 2005 (36.3) | |
Non-urgent | 14,913 (72.5) | 11,458 (76.1) | 3455 (62.6) | |
Access by EMS | 3375 (16.4) | 1928 (12.8) | 1447 (26.2) | 0.000 |
Symptoms > 24 h | 10,145 (49.3) | 7440 (49.4) | 2705 (49) | 0.637 |
Refusal of hospitalization | 2305 (11.2) | 1644 (10.9) | 661 (12) | 0.032 |
Associated complaints | ||||
Fever | 7782 (37.8) | 6125 (40.7) | 1657 (30) | 0.000 |
Vomiting | 12,157 (59.1) | 8811 (58.5) | 3346 (60.6) | 0.006 |
Nausea | 7745 (37.6) | 5898 (39.2) | 1847 (33.5) | 0.000 |
Abdominal pain | 12,297 (59.7) | 9432 (62.6) | 2865 (51.9) | 0.000 |
Chest pain | 990 (4.8) | 673 (4.5) | 317 (5.7) | 0.000 |
Syncope | 1791 (8.7) | 1099 (7.3) | 692 (12.5) | 0.000 |
Melena | 190 (0.9) | 108 (0.7) | 82 (1.5) | 0.000 |
Rectorrhagia | 756 (3.7) | 510 (3.4) | 246 (4.5) | 0.000 |
Belching/hiccups | 95 (0.5) | 66 (0.4) | 29 (0.5) | 0.413 |
Malaise | 3134 (15.2) | 2114 (14) | 1020 (18.5) | 0.000 |
Laboratory parameters | ||||
Hb (g/dL) | 13.7 (12.6–14.8) | 13.9 (12.9–15) | 13.1 (11.8–14.3) | 0.000 |
WBC (cell/mm3) | 8.58 (6.67–11] | 8.6 (6.7–11.1) | 8.5 (6.6–10.89) | 0.048 |
Creatinine (mg/dL) | 0.79 (0.65–0.98) | 0.76 (0.64–0.91) | 0.9 (0.71–1.18) | 0.000 |
Blood glucose (mg/dL) | 103 (92–120) | 100 (89–113) | 115 (99–138) | 0.000 |
Procalcitonin (ng/dL) | 0.050 (0.05–0.1) | 0.05 (0.05–0.09) | 0.05 (0.05–0.11) | 0.021 |
CRP (mg/L) | 6.9 (1.0–26.9) | 5.95 (0.8–24.77) | 9.8 (2–34.7) | 0.000 |
Clinical history | ||||
Diverticulosis | 904 (4.4) | 341 (2.3) | 563 (10.2) | 0.000 |
GERD | 707 (3.4) | 552 (3.7) | 1555 (2.8) | 0.003 |
IBD | 424 (2.1) | 348 (2.3) | 76 (1.4) | 0.000 |
Cardiac disease | 1392 (6.8) | 453 (3) | 939 (17) | 0.000 |
COPD | 585 (2.8) | 221 (1.5) | 364 (6.6) | 0.000 |
Diabetes | 1461 (7.1) | 521 (3.5) | 940 (17) | 0.000 |
Chronic renal failure | 269 (1.3) | 98 (0.7) | 171 (3.1) | 0.000 |
Liver disease | 219 (1.1) | 124 (0.8) | 95 (1.7) | 0.000 |
Dementia | 252 (1.2) | 17 (0.1) | 235 (4.3) | 0.000 |
Prescription at discharge | ||||
No antibiotic/probiotic | 15,092 (73.3) | 10,913 (72.4) | 4179 (75.2) | 0.045 |
Only antibiotic | 4411 (21.4) | 3299 (21.9) | 112 (20.3) | 0.001 |
Non-absorbable | 2012 (9.1) | 1480 (9.3) | 532 (9.6) | 0.086 |
Absorbable | 2965 (14.4) | 2172 (14.4) | 793 (14.4) | 0.063 |
Antibiotic (any)+ probiotic | 363 (1.8) | 276 (1.8) | 87 (1.6) | 0.065 |
Only probiotic | 715 (3.5) | 575 (3.8) | 140 (2.5) | 0.000 |
Amoxicillin | 44 (0.2) | 32 (0.2) | 12 (0.2) | 0.945 |
Amoxicillin/clavulanic acid | 493 (2.4) | 384 (2.5) | 109 (2.0) | 0.017 |
Azithromycin | 199 (1.0) | 139 (0.9) | 60 (1.1) | 0.285 |
Clarithromycin | 21 (0.1) | 15 (0.1) | 6 (0.1) | 0.855 |
Ceftriaxone | 226 (1.1) | 140 (0.9) | 86 (1.6) | 0.000 |
Levofloxacin | 315 (1.5) | 216 (1.4) | 99 (1.8) | 0.062 |
Ciprofloxacin | 1729 (8.4) | 1327 (8.8) | 402 (7.3) | 0.000 |
Fluoroquinolones | 2044 (9.9) | 1543 (10.2) | 501 (9.1) | 0.013 |
Metronidazole | 404 (2) | 269 (1.8) | 135 (2.4) | 0.002 |
Vancomycin | 21 (0.1) | 12 (0.1) | 9 (0.2) | 0.097 |
Doxycycline | 31 (0.2) | 30 (0.2) | 1 (0) | 0.003 |
Variable | Readmission within 7 Days | Univariate p Value | Odds Ratio [95% Confidence Interval] | Multivariate p Value | |
---|---|---|---|---|---|
YES (n. 1216) | NO (n. 19,365) | ||||
Males | 506 (41.6) | 7601 (39.3) | 0.102 | ||
Age (years) | 51 (35–69) | 48 (33–66) | 0.000 | ||
Age (years) | 0.000 | ||||
18–65 | 825 (67.8) | 14,238 (73.5) | |||
>65 | 391 (32.2) | 5127 (26.5) | 1.329 [1.170–1.510] | 0.000 | |
Triage code | |||||
Emergency | 5 (0.4) | 115 (0.6) | |||
Urgent | 341 (28) | 5207 (26.9) | 0.504 | ||
Non-urgent | 870 (71.5) | 14,043 (72.5) | |||
Access to EMS | 166 (13.7) | 3209 (16.6) | 0.008 | 0.811 [0.681–0.967] | 0.019 |
Symptoms > 24 h | 670 (55.1) | 9475 (48.9) | 0.000 | 1.240 [1.099–1.398] | 0.000 |
Length of stay in the ED (hours) | 7.1 [4.7–14.3] | 7.2 [4.6–14.5] | 0.956 | ||
Refusal of hospitalization | 206 (16.9) | 2099 (10.8) | 0.000 | 1.699 [1.452–1.989] | 0.000 |
Associated complaints | |||||
Fever | 461 (37.9) | 7321 (37.8) | 0.941 | ||
Vomiting | 729 (60) | 11,428 (59.0) | 0.519 | ||
Nausea | 455 (37.4) | 7290 (37.6) | 0.874 | ||
Abdominal pain | 748 (61.5) | 11,549 (59.6) | 0.196 | ||
Chest pain | 57 (4.7) | 933 (4.8) | 0.837 | ||
Syncope | 76 (6.3) | 1715 (8.9) | 0.002 | 0.732 [0.573–0.935] | 0.012 |
Melena | 10 (0.8) | 180 (0.9) | 0.705 | ||
Rectorrhagia | 43 (3.5) | 713 (3.7) | 0.793 | ||
Belching/hiccups | 5 (0.4) | 90 (9.5) | 0.789 | ||
Malaise | 181 (14.9) | 2953 (15.2) | 0.732 | ||
Laboratory parameters | |||||
Hb (g/dL) | 13.5 [12.1–14.5] | 13.7 [12.6–14.9] | 0.000 | ||
WBC (cell/mm3) | 8.32 [6.3–10.8] | 8.5 [6.7–11.4] | 0.054 | ||
Creatinine (mg/dL) | 0.81 [0.66–1.03] | 0.8 [0.70–1.0] | 0.140 | ||
Blood glucose (mg/dL) | 102 (90–120.5) | 103 (92–120) | 0.523 | ||
Procalcitonin (ng/dL) | 0.05 [0.05–0.11] | 0.05 [0.05–0.10] | 0.979 | ||
CRP (mg/L) | 8.5 [1.2–28.4] | 6.8 [1.2–26.9] | 0.449 | ||
Clinical history | |||||
Diverticulosis | 46 (3.8) | 858 (4.4) | 0.285 | ||
GERD | 33 (2.7) | 674 (3.8) | 0.154 | ||
IBD | 22 (1.8) | 401 (2.1) | 0.525 | ||
Cardiac disease | 92 (7.6) | 1300 (6.7) | 0.251 | ||
COPD | 42 (3.5) | 543 (2.8) | 0.186 | ||
Diabetes | 100 (8.2) | 1361 (7.0) | 0.115 | ||
Chronic renal failure | 28 (2.3) | 241 (1.2) | 0.002 | 1.618 [1.083–2.416] | 0.019 |
Liver disease | 23 (1.9) | 196 (1.0) | 0.004 | 1.696 [1.093–2.631] | 0.018 |
Dementia | 16 (1.3) | 236 (1.2) | 0.765 | ||
Prescription at discharge | |||||
No antibiotics/probiotics | 924 (76.0) | 14,168 (73.2) | 0.154 | ||
Only antibiotics | 238 (19.6) | 4173 (21.5) | 0.103 | 0.870 [0.749–1.010] | 0.680 |
Antibiotics+probiotics | 16 (1.3) | 347 (1.8) | 0.221 | 0.715 [0.430–1.188] | 0.195 |
Only probiotics | 38 (3.1) | 677(3.5) | 0.493 | 0.897 [0.642–1.254] | 0.525 |
Amoxicillin | 4 (0.3) | 454 (2.3) | 0.370 | ||
Amoxicillin/clavulanic acid | 39 (3.2) | 188 (1.0) | 0.056 | ||
Azithromycin | 11 (0.9) | 188 (1.0) | 0.819 | ||
Clarithromycin | 0 (0.0) | 21 (0.1) | 0.251 | ||
Ceftriaxone | 21 (1.7) | 205 (1.1) | 0.030 | ||
Levofloxacin | 18 (1.5) | 297 (1.5) | 0.883 | ||
Ciprofloxacin | 79 (6.5) | 1650 (8.5) | 0.014 | ||
Fluoroquinolones | 97 (8.0) | 1947 (10.1) | 0.019 | ||
Metronidazole | 21 (1.7) | 383 (2.0) | 0.541 | ||
Vancomycin | 2 (0.2) | 19 (0.1) | 0.482 | ||
Doxycycline | 3 (0.2) | 28 (0.1) | 0.373 |
Variable | Readmission within 7 Days | Univariate p Value | Odds Ratio [95% Confidence Interval] | Multivariate p Value | |
---|---|---|---|---|---|
YES (N 825) | NO (14,238) | ||||
Sex (male) | 335 (40.6) | 5700 (40) | 0.744 | ||
Age (years) | 41 (30–52) | 40 (29–51) | 0.116 | ||
Triage code | 0.090 | ||||
Emergency | 3 (0.4) | 59 (0.4) | |||
Urgent | 220 (26.7) | 3323 (23.3) | |||
Non-urgent | 602 (73) | 10,856 (76.2) | |||
Access to EMS | 83 (10.1) | 1845 (13) | 0.015 | 0.781 [0.615–0.991] | 0.042 |
Symptoms > 24 h | 445 (53.9) | 6995 (49.1) | 0.007 | 1.195 [1.034–1.381] | 0.016 |
Refusal of hospitalization | 144 (17.5) | 1500 (10.5) | 0.000 | 1.823 [1.509–2.203] | 0.000 |
Length of stay in the ED (hours) | 6.7 [4.5–11.8] | 6.7 [4.4–11.8] | 0.803 | ||
Associated complaints | |||||
Fever | 318 (38.5) | 5807 (40.8) | 0.203 | ||
Vomiting | 492 (59.6) | 8319 (58.4) | 0.494 | ||
Nausea | 331 (40.1) | 5567 (39.1) | 0.559 | ||
Abdominal pain | 529 (64.1) | 8903 (62.5) | 0.358 | ||
Chest pain | 39 (4.7) | 634 (4.5) | 0.711 | ||
Syncope | 43 (5.2) | 1056 (7.4) | 0.018 | 0.753 [0.547–1.037] | 0.083 |
Melena | 5 (0.6) | 103 (0.7) | 0.698 | ||
Rectorrhagia | 33 (4.0) | 477 (3.4) | 0.316 | ||
Belching/hiccups | 2 (0.2) | 64 (0.4) | 0.381 | ||
Malaise | 113 (13.7) | 2001 (14.1) | 0.774 | ||
Laboratory parameters | |||||
Hb (g/dL) | 13.5 [12.3–14.6] | 14.1 [12.9–15.1] | 0.000 | ||
WBC (cell/mm3) | 8.53 [6.62–10.77] | 8.60 [6.70–11.12] | 0.178 | ||
Creatinine (mg/dL) | 0.76 [0.63–0.91] | 0.76 [0.64–0.91] | 0.504 | ||
Blood glucose (mg/dL) | 99 (88–114) | 100 (89–113) | 0.314 | ||
Procalcitonin (ng/dL) | 0.05 [0.05–0.10] | 0.05 [0.05–0.09] | 0.812 | ||
CRP (mg/L) | 6.6 [1–26.5] | 5.8 [0.8–24.8] | 0.600 | ||
Clinical history | |||||
Diverticulosis | 19 (2.3) | 322 (2.3) | 0.938 | ||
GERD | 23 (2.8) | 529 (3.7) | 0.168 | ||
IBD | 17 (2.1) | 331 (2.3) | 0.623 | ||
Cardiac Disease | 29 (3.5) | 424 (3.6) | 0.380 | ||
COPD | 15 (1.8) | 206 (1.4) | 0.388 | ||
Diabetes | 35 (4.2) | 486 (3.4) | 0.205 | ||
Chronic renal failure | 13 (1.6) | 85 (0.6) | 0.001 | 2.404 [1.322–4.373] | 0.004 |
Liver disease | 16 (1.9) | 108 (0.8) | 0.000 | 2.236 [1.304–3.835] | 0.003 |
Dementia | 4 (0.5) | 13 (0.1) | 0.001 | 5.962 [1.931–18.405] | 0.002 |
Prescription at discharge | |||||
No antibiotics/probiotics | 630 (76.4) | 10,283 (72.2) | 0.072 | ||
Only antibiotics | 157 (19.0) | 3142 (22.1) | 0.040 | 0.825 [0.687–0.991] | 0.039 |
Antibiotics+probiotics | 11 (1.3) | 265 (1.9) | 0.272 | 0.700 [0.380–1.289] | 0.252 |
Only probiotics | 27 (3.3) | 548 (3.8) | 0.401 | 0.860 [0.578–1.278] | 0.455 |
Amoxicillin | 4 (0.5) | 28 (0.2) | 0.080 | ||
Amoxicillin/clavulanic acid | 31 (3.8) | 353 (2.5) | 0.024 | ||
Azithromycin | 9 (1.1) | 130 (0.4) | 0.603 | ||
Clarithromycin | 0 (0.0) | 15 (0.1) | 0.351 | ||
Ceftriaxone | 14 (1.7) | 126 (0.9) | 0.018 | ||
Levofloxacin | 12 (1.5) | 204 (1.4) | 0.959 | ||
Ciprofloxacin | 54 (6.5) | 1273 (8.9) | 0.018 | ||
Fluoroquinolones | 66 (8.0) | 1477 (10.4) | 0.029 | ||
Metronidazole | 12 (1.5) | 257 (1.8) | 0.460 | ||
Vancomycin | 1 (0.1) | 11 (0.1) | 0.664 | ||
Doxycycline | 3 (0.4) | 27 (0.2) | 0.276 |
Variable | Readmission within 7 Days | Univariate p Value | Odds Ratio [95% Confidence Interval] | Multivariate p Value | |
---|---|---|---|---|---|
YES (N 391) | NO (N 5127) | ||||
Sex (male) | 171 (43.7) | 1901 (37.1) | 0.009 | 1.291 [1.047–1.592] | 0.017 |
Age (years) | 75 (70–81) | 76 (70–82) | 0.55 | ||
Triage code | |||||
Emergency | 2 (0.5) | 56 (1.1) | 0.337 | ||
Urgent | 121 (30.9) | 1884 (26.7) | 0.032 | 1.702 [0.409–7.076] | 0.465 |
Non-urgent | 268 (68.5) | 3187 (62.2) | 2.029 [0.490–8.404] | 0.329 | |
Access to EMS | 83 (21.2) | 1364 (26.6) | 0.020 | 0.861 [0.663–1.119] | 0.264 |
Symptoms > 24 h | 225 (57.5) | 2480 (48.4) | 0.000 | 1.299 [1.041–1.622] | 0.021 |
Length of stay in the ED (hours) | 8.6 [5.1–21.1] | 9.0 [5.5–24.0] | 0.102 | ||
Refusal of hospitalization | 62 (15.9) | 599 (11.7) | 0.014 | 1.438 [1.077–1.918] | 0.014 |
Associated complaints | |||||
Fever | 143 (36.6) | 1514 (29.5) | 0.003 | 1.336 [1.072–1.665] | 0.010 |
Vomiting | 237 (60.6) | 3109 (60.6) | 0.992 | ||
Nausea | 124 (31.7) | 1723 (33.6) | 0.445 | ||
Abdominal pain | 219 (56) | 2646 (51.6) | 0.093 | ||
Chest pain | 18 (4.6) | 299 (5.8) | 0.314 | ||
Syncope | 33 (8.4) | 659 (12.9) | 0.011 | 0.682 [0.467–0.996] | 0.047 |
Melena | 5 (1.3) | 77 (1.5) | 0.725 | ||
Rectorrhagia | 10 (2.6) | 236 (4.6) | 0.059 | ||
Belching/hiccups | 3 (0.8) | 26 (0.5) | 0.493 | ||
Malaise | 68 (17.4) | 952 (18.6) | 0.563 | ||
Laboratory parameters | |||||
Hb (g/dL) | 13.2 [11.7–14.4] | 13.1 [11.9–14.2] | 0.716 | ||
WBC (cell/mm3) | 8.08 [5.81–10.89] | 8.50 [6.70–10.90] | 0.177 | ||
Creatinine (mg/dL) | 1.04 [0.80–1.37] | 0.90 [0.71–1.17] | 0.003 | ||
Blood glucose (mg/dL) | 116 (96–131) | 115 (100–138) | 0.537 | ||
Procalcitonin (ng/dL) | 0.06 [0.05–0.15] | 0.05 [0.05–0.11] | 0.693 | ||
CRP (mg/L) | 11.9 [2.3–43.0] | 9.5 [1.9–34.5] | 0.596 | ||
Clinical history | |||||
Diverticulosis | 27 (6.9) | 536 (10.5) | 0.025 | 0.601 [0.401–0.901] | 0.014 |
GERD | 10 (2.6) | 145 (2.8) | 0.755 | ||
IBD | 5 (1.3) | 71 (1.4) | 0.862 | ||
Cardiac disease | 63 (16.1) | 876 (17.1) | 0.621 | ||
COPD | 27 (6.9) | 337 (6.6) | 0.799 | ||
Diabetes | 65 (16.6) | 875 (17.1) | 0.822 | ||
Chronic renal failure | 15 (3.8) | 156 (3.0) | 0.383 | ||
Liver disease | 7 (1.8) | 88 (1.7) | 0.914 | ||
Dementia | 12 (3.1) | 223 (4.3) | 0.227 | ||
Prescription at discharge | |||||
No antibiotics/probiotics | 294 (75.2) | 3885 (75.8) | 0.931 | ||
Only antibiotics | 81 (20.7) | 1031 (20.1) | 0.773 | 0.974 [0.7491.266] | 0.843 |
Antibiotics+probiotics | 5 (1.3) | 82 (1.6) | 0.624 | 0.781 [0.312–1.955] | 0.598 |
Only probiotics | 11 (2.8) | 129 (2.5) | 0.719 | 1.105 [0.587–2.081] | 0.757 |
Amoxicillin | 0 (0.0) | 12 (0.2) | 0.338 | ||
Amoxicillin/clavulanic acid | 8 (2.0) | 101 (2) | 0.917 | ||
Azithromycin | 2 (0.5) | 58 (1.1) | 0.255 | ||
Clarithromycin | 0 (0.0) | 6 (0.1) | 0.499 | ||
Ceftriaxone | 7 (1.8) | 7.9 (1.5) | 0.701 | ||
Levofloxacin | 6 (1.5) | 93 (1.8) | 0.688 | ||
Ciprofloxacin | 25 (6.4) | 377 (7.4) | 0.482 | ||
Fluoroquinolones | 31 (7.9) | 470 (9.2) | 0.411 | ||
Metronidazole | 9 (2.3) | 126 (2.5) | 0.848 | ||
Vancomycin | 1 (0.3) | 8 (0.2) | 0.638 | ||
Doxycycline | 0 (0.0) | 1 (0) | 0.782 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Covino, M.; Gallo, A.; Rognoni, F.M.; Parlangeli, M.C.; Simeoni, B.; Franceschi, F.; Landi, F.; Montalto, M. Acute Diarrhea in a Tertiary Emergency Department: From Readmission Determinants to Antibiotic Prescription. Antibiotics 2024, 13, 891. https://doi.org/10.3390/antibiotics13090891
Covino M, Gallo A, Rognoni FM, Parlangeli MC, Simeoni B, Franceschi F, Landi F, Montalto M. Acute Diarrhea in a Tertiary Emergency Department: From Readmission Determinants to Antibiotic Prescription. Antibiotics. 2024; 13(9):891. https://doi.org/10.3390/antibiotics13090891
Chicago/Turabian StyleCovino, Marcello, Antonella Gallo, Fiammetta Maria Rognoni, Maria Caterina Parlangeli, Benedetta Simeoni, Francesco Franceschi, Francesco Landi, and Massimo Montalto. 2024. "Acute Diarrhea in a Tertiary Emergency Department: From Readmission Determinants to Antibiotic Prescription" Antibiotics 13, no. 9: 891. https://doi.org/10.3390/antibiotics13090891
APA StyleCovino, M., Gallo, A., Rognoni, F. M., Parlangeli, M. C., Simeoni, B., Franceschi, F., Landi, F., & Montalto, M. (2024). Acute Diarrhea in a Tertiary Emergency Department: From Readmission Determinants to Antibiotic Prescription. Antibiotics, 13(9), 891. https://doi.org/10.3390/antibiotics13090891